PKD2 and non-small cell lung carcinoma: For example, miR-1271 upregulation enhances cisplatin sensitivity in gastric cancer cells and miR-106b-5p upregulation or PKD2 (polycystin 2, transient receptor potential cation channel) inhibition could increase NSCLC cell sensitivity to cisplatin [24, 25].